Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is absolutely true that Gartner has no valid data at all on the use of DR70 with smokers and former smokers and his ccurrent numbers are just BS at best.
Fibrin is mostly an indicator of rapid tissue growth for whatever reason. The use of the test for smokers would still trigger rapid tissue growth of other types of cancer in addition to the already huge list of non cancerous high fibren levels.
Gartners test will never get FDA approval but it may indeed sucker some "fish" and be a money winner for Gartner's personal payroll. Gartner knows this and will avoid the "hard questions".
As I stated before, I called the number listed on the website. An office manager named Jennifer answered. I asked her some simple questions like how many employees, and she refuse to answer. She wanted to know why I was calling and I just stated that another investor had read the press release and asked me to check out the company. She took my number and said Gartner would call me back.
No call back of course. Gartner wants ZERO hard questions and just wants to speak with "fish".
Here are some things to consider. When the LC Sentinel test was on the provista pipeline, it was just a lung cancer test. It absolutely did not have any restrictions about being used for smokers and former smokers.
These are the numbers given in a press release about the partnership with Radient at that time. This was strictly a DR70 test and ALL the reagents would be provided by Radient.
"The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97."
http://finance.yahoo.com/news/Radient-Pharmaceuticals-and-iw-1271623575.html
Now look at the "fundable" data.
"The Lung Cancer Test can detect the presence of lung cancer in high-risk populations with a sensitivity of 87% and a specificity of 95%. The overall accuracy of the test is 97%, defined by the area under the receiver-operating characteristic (ROC) curve."
http://www.fundable.com/the-lung-cancer-test
It is the identical numbers stated by provista when it had zero restrictions on who was given the test.
To have the same numbers is IMPOSSIBLE
I called GCDX. An office manager named Jennifer answered. She said Gartner would call me back.
IMO, this is Gartner's latest attempt to find investment money. There is no description of the final validation test at all. If there really was any "final validation test", he would have given an expected end date for the test. It is just open ended without a date for expected sales.
Attention: investment suckers please line up!
DC, BIG Glitch in your RXPC spin.
"Global Cancer Diagnostics Announces Start of Final Validation Study for Its New Blood Test for the Early Detection of Lung Cancer"
Gartner is pressing on with his lung cancer test that is not connected with RXPC.
http://www.businesswire.com/news/home/20140827006035/en/Global-Cancer-Diagnostics-Announces-Start-Final-Validation#.U_72JyTn82o
Jimtash, you are looking at an older version of LinkedIn. This is the new one. It states that he started Provista life sciences and sold it.
http://www.linkedin.com/pub/william-gartner/78/904/31
William Gartner's Overview
Current CEO at Global Cancer Diagnostics Inc.
President & CEO at Global Cancer Diagnostics Inc.
Education Lewis University
Northwestern University
Connections
43 connections
William Gartner's Summary
William Gartner has founded a number of laboratory companies focusing on medical diagnostics and environmental marketing. Most recently, one of those companys developed a blood test for Alzheimer’s disease in collaboration with the Paul Fleischig Institute at the University of Leipzig. In the last year, Mr. Gartner founded Global Cancer Diagnostics Inc. to commercialize a blood test for lung cancer that detects the disease in Stages 1 and 2 when it can be treated with much higher survivability rates. Those efforts are coming to fruition with the planned introduction of the GCD Lung Cancer Test. The test will be sold through physicians and directly to consumers in the 27 states that allow DTC diagnostics. The most remarkable features are the ROC Accuracy of the test at 97.2% and its price at $99, eliminating the need for insurance reimbursement in most cases. With 43,000,000 current smokers in the U.S. alone who should receive annual testing, the market size is staggering.
In 2003, Mr. Gartner formed what became Provista Life Sciences to commercialize a highly accurate blood test for breast cancer. That company was sold in 2011 and now operates as Provista Diagnostics Inc. That company is now working toward FDA approval of the blood test for breast cancer.
Mr. Gartner’s arrival in Phoenix initiated his first divergence from the laboratory business with the design and sale of a complete range of golf clubs. His design of an early “utility club” called the Power Spoon, won an award from Golf Digest as the best new utility club of 1988. It made its first appearance in the Phoenix Open Silver Pro-Am that year.
In the years in Illinois and later in Phoenix, Mr. Gartner has owned 4 different laboratory companies with one, Acculabs Inc., becoming the largest private company contracted to many agencies in the federal government to analyze a wide variety of soils, grasses, animals, etc. to look for radiation residuals around facilities such as Pentax.
William Gartner's Experience
CEO
Global Cancer Diagnostics Inc.
July 2012 – Present (2 years 2 months)
Founded the Company and structured the initial financing to undertake the commercialization of a blood test for early stage lung cancer
President & CEO
Global Cancer Diagnostics Inc.
July 2011 – Present (3 years 2 months) 2343 W. University Dr. Tempe AZ 85281
Global Cancer Diagnostics is preparing to introduce a blood test for the detection of lung cancer in Stages 1 and 2. Expected commercialization date is May 1, 2014
On Donald Roberton's facebook page, it has the following entry on July 16, 2013.
"Left Job at Global Cancer Diagnostics."
Jim, Gartners original pitch when he attempted financing was to begin selling the DR70 test very soon after financing was obtained. The FDA has now made that impossible. There is no way at all for him to begin selling cancer diagnostic tests without the FDA stepping in and making him conduct expensive trials or just shutting him down.
He obviously is not paying as much attention to the project anymore because he has not even maintained current corporation filings nor did he pay his bill with Go Daddy. That is what that was all about. He just failed to pay the hosting fee.
If Gartner could somehow find financing from a foolish investor, he would indeed proceed because that was his plan in the first place. Pay himself a good salary while the investment money lasts.
This is indeed the Darren Brown you are dealing with. His work history in 2000 is with an accounting and on line tax filing company.
He and three other absconded with tax refunds. Darren Brown served 18 months in prison at exactly the same time Dennis Charter was also in jail.
These two probably met and became friends while in prison.
IMO, the only thing these guys wanted from Radient was any assets remaining. Thus far, nothing has proved me wrong.
In 2001, a former director of TRADC and Online Returns, Darren Brown, was jailed for two years (to serve 18 months) for his involvement with a company called Lateral Trading Limited. Brown and two other directors were found guilty of misappropriating $1.46 million of Lateral funds.
http://www.smartcompany.com.au/legal/16643-asic-moves-to-liquidate-tax-return-websites-over-claims-customer-money-was-used-to-buy-holiday-house.html#
https://www.asic.gov.au/asic/pdflib.nsf/LookupByFileName/00-104.pdf/$file/00-104.pdf
Bloomberg is obviously not a site with current information.
Since the FDA is not going to allow Gartner to sell his test, My guess is that Gartner aborted the change to the website.
What kind of idiot do you think Gartner is? He certainly is not going to put any significant amount of his own money in GCDx. GCDX is a scam to fleece investors, not fleece himself dry.
Dcspka stated: "The USA has less than 5% of the world's population. I feel the real success story will be cracking China/India/Eastern Europe."
Just looked at the worldwide sales of diagnostic tests. 26% were in the USA.
Jimtash, being legit is not the point. None of the tests sold by Provistaddx are currently FDA approved and the new FDA announcement is going to make Provista apply for approval or cease selling their tests. Ultimately, the tests may not be FDA approved.
This is a big deal for provista.
Agreed but usually, the overseas sales is small compared to any test sales in the US. DR70 never even had any US market.
IMO, at this point, Provista will be more concerned about staying in business with a product than anything else.
IMO, the new FDA regulations will bankrupt Provistadx.
There goes Provista's BT test. POOF
There goes Provistadx labs...One of the main offenders that will cease due to the FDA's new regulations.
The FDA just blew Gartner's GCDx out of the water. That was the end of his claiming they will be soon selling a lung cancer test.
It was obviously proving difficult for Gartner to obtain financing, now it will be totally impossible.
The FDA announced today new regulations planned for laboratory prepared cancer tests.
That will do in Gartner's attempt to sell his lung cancer test. That test will never be FDA approved and the FDA mentioned needing PMA's. That takes years.
Again, Gartner's website will never surface again.
FDA To Regulate Thousands Of Cancer, Genetic, And Other Diagnostics
The Food and Drug Administration unveiled plans to regulate thousands of diagnostic tests, including many coming from the exploding field of genetic research, to which it has until now turned a blind eye.
More than 11,000 of these tests, known as laboratory-developed tests, created by 2,000 different laboratories, could be included in the new regulatory framework, according to the FDA.
Living stated: "buying before revocation is considered bad timing."
Buying after a revocation settlement is ..... stupidity.
Living, Gartner's comment was just BS. If you are attempting to obtain investors, why would you shut down your website and leave it dormant for weeks just to change the website. That makes ZERO sense. Normal method is just to write the new one, upload it and you are done.
This website is expired just as I said. We just wait and I will be correct again.
Gartner has let the corporation registration expire and he has also let the GCDx website expire.
IMO, Gartner has not been able to obtain funding for his test.
When he cannot get funding for his intended use of DR70, why would he be involved in some fantasy "takeover" of Radient which also could not obtain funding.
"Our Process for Handling Expired Domain Names
The process we, the registrar, follow for expired domain names depends on your domain name extensions and their renewal settings. Prior to expiration, we send multiple emails to remind you to renew your domain names.
If you set your domain names to automatically renew, we attempt to renew the registrations for you the day after expiration. If we are unable to bill you, we park your expired domain names and notify you via email again.
If you set your domain names to manually renew and you let your domain names expire, we park your expired domain names and notify you via email again the day after expiration.
For expired .com, .net, .org, .info, .biz, .us, .ws, .name, .cc, .mobi, .me, or .tv domain name registrations, we hold your domain name for approximately 42 days before canceling it. Domain name renewal during this period is subject to applicable renewal and redemption fees. For more information, see What happens after domain names expire? and Recovering Expired Domain Names."
What they do not say in the above is that they own the site after the 42 days and attempt to resell it if the domain name is deemed to have value.
No Jimtash, he did not renew it. The new date is from go daddy in their attempt to sell the domain name.
Gartner's domain expired in may. After the grace period it belonged to go daddy. Go Daddy can put any expiration date on a site they own.
Jimtash, do a little research into how go daddy handles domains that expire. This is exactly what multiple former go daddy clients describe. Go Daddy holds their site hostage until the client pays fees and penalties.
If go daddy computers think the site has value, they will offer it for sale just like you see today, parked for free. Go Daddy determines the value by the number of hits the site gets. The site has been getting multiple hits just like both you and I just looked at the site.
But whatever you think is fine with me. If it helps you feel comfort with the money you lost, then Gartner is your hero.
The GCDx website.
I have been doing some research on his website. This is what I have found out. If you fail to renew the domain name, go daddy has some options. They can just dump it or if they think the name might have some value, then they park it for free in an attempt to sell the domain.
If you intentionally park a domain with go daddy, they charge $4 a month. It is not free.
Gartner's domain name actually expired on May 15 and it went through the grace period before Go Daddy took possession of the name.
If Gartner wants the domain back, he is going to have to buy it back from go daddy with some stiff penalty fees.
For those who contacted Gartner, I think they got a line of BS. There is not going to be anything more done without financing.
Look up the whois info and the email contact. Registrant Email: e mail at domains by proxy dot com. That is a go daddy site.
I found another site where they were still selling Dr70 as of Jul 2014 so it is difficult to see what is really going on. A different company is also offering Onko Sure and has some of the old Radient pages on their website. More than one company seems to be distributing the test in Taiwan.
http://www.bioclub.com.tw/en/visitorExhibitorDetail.asp?comNo=227775
That one shows Uni-pharma.com as the website but nothing on the site about onko sure or DR70.
Onko-Sure ® distributor in Taiwan
Arima Pharmaceutical Co., Ltd.
Neihu, Taipei 114, Sec Jiuzong 3rd Floor, No. 17, Lane 171 TEL: (02) 2658-2577
This company has a website promoting DR70 in Taiwan.
Address: Taipei 114, Lane 171, Sec Jiuzong Neihu District, 3rd Floor, No. 17 TEL: (02) 2658-2577
Copyright © 2014 Huayu Pharmaceutical Co., Ltd.
http://translate.google.com/translate?hl=en&sl=zh-TW&u=http://www.dr70.com.tw/web/features&prev=/search%3Fq%3Donko%2Bsure%26lr%3D%26cr%3DcountryTW%26as_qdr%3Dall%26tbs%3Dctr:countryTW
Here is the website for Uni Pharma.
http://www.uni-pharma.com/products/cpzsengliash.html#
There is no mention of Onko Sure nor Radient as one of the American partners.
The ad I posted in the pdf was from Oct 2013. Is uni no longer even selling onko sure?
Living, it was an advertisement by Uni included in the pdf.
Uni was wanting exactly what Gartner wanted. The ability to make and sell DR70 after the patent expired.
The Uni agreement is carefully worded so that everything is cancelled when the last ISSUED patent expires. The same goes for the agreement with Gartner.
As for the new website. Here is my guess. The Aussies have gone bare bones for expenses. Stopped a multipage website $$$. Disconnected the phones. Ceased all obligations.
They then registered a cheap one page website. IMO, the purpose of that site is to indeed communicate with shareholders. As I mentioned before, they may post a short "we attempted to reorganize but failed. We have monetized all of the assets remaining but the company is insolvent. All of the patents have expired and the remaining application was rejected by the patent board. We have resigned from the BOD and the company is dissolved."
The Aussies.
From the Uni agreement:
"This Agreement shall become effective upon the date of signing by both Parties and continue in effect until the earlier to occur of: (i) expiration of the last patent issued to RXPC for the Licensed Products."
That's it Wolfie, the last issued patent has expired and the agreement is now VOIDED.
Uni has no agreement and pays no royalties.
http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm
Wolfie, are you running out of spins?
Uni manufacturing and selling generic DR70 is good news?
Uni is now the newly spun "takeover" group.
You seem to be in a mighty struggle gasping for air.
There is no takeover group and the Aussies have just looted what is left. Charter stole the $437,000 back in 2003 but got caught and was sent to prison. Is he going to get caught for looting the remaining assets of Radient?
IMO, if the Radient-diagnostic website does come up, it will probably state that reorganization was not possible and they intend to sell off assets. They probably wont tell you that all of the former Radient equipment is already in Honk Kong setting up their own private company.
Once a thief, always a thief. That seems to be the pattern.
Wolfie is totally wrong again.
He stated: " you are forgetting the most important fact ..The agreement with Uni was with AMDL Inc "
No it was not.
It was with AMDL Diagnostics, which was a subsidiary of Radient Pharmaceuticals along with Nuvax. The subsidiarys of Radient have gone down the tubes along with Radient.
You seem to have a very low standard for "best news ever". The fact that Uni is manufacturing and selling DR70 and paying no royalties is far from good news at all.
Another company selling generic DR70
Hangzhou Eastbiopharm Co., Ltd.
Contact Details Company Profile
Human tumor marker DR-70 for lung cancer,DR-70TM ELISA Kit
Human tumor marker DR-70 for lung cancer,DR-70TM ELISA Kit
Looks like Uni is doing their own manufacturing
Uni Pharma Co., Ltd.
(Onko-Sure Asia Pacific Manufacturing and Distribution Headquarter)
http://pharmaboardroom.com/wp-content/files_mf/1391174479taiwanpharmareportnovember20131.pdf